Ambulatory use of blinatumomab in paediatric patients with relapsed or refractory B-cell acute lymphoblastic leukaemia at a single centre in South Africa

Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer, with B-ALL comprising approximately 85% of all cases. Despite a high cure rate, those with refractory disease and/or relapsed (R/R) B-ALL have an inferior overall survival. Blinatumomab, a novel therapy, is a bispecific cluster...

Full description

Bibliographic Details
Published in:South African Journal of Oncology
Main Authors: Nadia Beringer, Kate Gwynneth Bennett
Format: Article
Language:English
Published: AOSIS 2026-05-01
Subjects:
Online Access:https://sajo.org.za/index.php/sajo/article/view/365